Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

456 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations.
Conforti F, Pala L, Pagan E, Rocco EG, Bagnardi V, Montagna E, Peruzzotti G, De Pas T, Fumagalli C, Pileggi S, Pesenti C, Marchini S, Corso G, Marchio' C, Sapino A, Graffeo R, Collet L, Aftimos P, Sotiriou C, Piccart M, Gelber RD, Viale G, Colleoni M, Goldhirsch A. Conforti F, et al. Among authors: gelber rd. Breast. 2021 Oct;59:94-101. doi: 10.1016/j.breast.2021.06.011. Epub 2021 Jun 26. Breast. 2021. PMID: 34217971 Free PMC article.
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam CM, Lindtner J, Erzen D, Snyder R, Collins J, Fey MF, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Colleoni M, et al. Among authors: gelber rd. J Clin Oncol. 2005 Mar 1;23(7):1390-400. doi: 10.1200/JCO.2005.06.052. J Clin Oncol. 2005. PMID: 15735115 Clinical Trial.
Prediction of cancer outcome with microarrays.
Goldhirsch A, Gelber RD, Viale G, Colleoni M, Coates AS. Goldhirsch A, et al. Among authors: gelber rd. Lancet. 2005 May 14-20;365(9472):1685-6; author reply 1686. doi: 10.1016/S0140-6736(05)66542-7. Lancet. 2005. PMID: 15894095 No abstract available.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Piccart-Gebhart MJ, et al. Among authors: gelber rd. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. N Engl J Med. 2005. PMID: 16236737 Free article. Clinical Trial.
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
International Breast Cancer Study Group; Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD. International Breast Cancer Study Group, et al. Among authors: gelber s, gelber rd. J Clin Oncol. 2006 Mar 20;24(9):1332-41. doi: 10.1200/JCO.2005.03.0783. Epub 2006 Feb 27. J Clin Oncol. 2006. PMID: 16505417 Clinical Trial.
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B; International Breast Cancer Study Group. Regan MM, et al. Among authors: gelber rd. J Natl Cancer Inst. 2006 Nov 1;98(21):1571-81. doi: 10.1093/jnci/djj415. J Natl Cancer Inst. 2006. PMID: 17077359 Free article.
456 results